APOA1 and ovarian adenocarcinoma: To examine a causal role of reduced APOA1/HDL levels in patients suffering from ovarian cancer, mouse in vivo studies with ID8 ovarian adenocarcinoma cells revealed a significant antitumor capacity of the human Apoa1 transgene and the therapeutic administration of APOA1 mimetic peptides (4).